Polylite Taiwan (1813) reported revenue of NT$21.9 million for Oct 2026, +0.6% year on year and -2.0% from the previous month. Revenue for Jan–Oct 2026 was NT$237.5 million (-7.2% year on year).
In Oct 2026, it ranked No. 122 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$21.9 million | +0.6% | -2.0% |
| Sep 2026 | NT$22.4 million | -6.9% | -1.6% |
| Aug 2026 | NT$22.7 million | +0.6% | -0.3% |
| Jul 2026 | NT$22.8 million | -2.2% | +4.1% |
| Jun 2026 | NT$21.9 million | -14.4% | -13.9% |
| May 2026 | NT$25.4 million | -10.4% | -4.6% |
| Apr 2026 | NT$26.6 million | -0.3% | -0.4% |
| Mar 2026 | NT$26.7 million | -13.6% | +41.1% |
| Feb 2026 | NT$19 million | -36.2% | -32.6% |
| Jan 2026 | NT$28.1 million | +21.9% | +1.0% |
| Dec 2025 | NT$27.8 million | +21.7% | +36.2% |
| Nov 2025 | NT$20.4 million | -18.2% | -6.2% |
| Oct 2025 | NT$21.8 million | -12.0% | -9.3% |
| Sep 2025 | NT$24 million | -6.1% | +6.4% |
| Aug 2025 | NT$22.6 million | +0.2% | -3.0% |
| Jul 2025 | NT$23.3 million | -19.4% | -8.8% |
| Jun 2025 | NT$25.5 million | +25.3% | -10.0% |
| May 2025 | NT$28.4 million | -5.6% | +6.2% |
| Apr 2025 | NT$26.7 million | -11.6% | -13.7% |
| Mar 2025 | NT$30.9 million | +20.5% | +4.1% |
| Feb 2025 | NT$29.7 million | +18.8% | +28.9% |
| Jan 2025 | NT$23.1 million | -20.2% | +0.9% |
| Dec 2024 | NT$22.9 million | -6.4% | -8.4% |
| Nov 2024 | NT$25 million | -8.9% | +0.9% |
| Oct 2024 | NT$24.8 million | -19.7% | -3.3% |
Jan–Oct 2026 cumulative: NT$237.5 million (-7.2% YoY)
Other Biotech & Medical companies
Compare with peers: Polylite Taiwan vs PEC / Polylite Taiwan vs Lotus Pharm / Polylite Taiwan vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16